Showing posts with label genetic testing. Show all posts
Showing posts with label genetic testing. Show all posts

Jul 14, 2011

Eat broccoli and live longer

To the likely delight of nagging parents, a new study shows that people who eat more fruit and veggies tend to live longer.
Plants from the mustard family -- including broccoli, cabbage, and cauliflower -- seem particularly beneficial, although the study can't prove that eating more vegetables automatically increases longevity.It's possible, for instance, that those who consume lots of produce also have a healthier lifestyle in general. Still, the findings "provide strong support for the current recommendation to increase vegetable consumption to promote cardiovascular health and overall longevity," study researcher Dr. Xianglan Zhang, of Vanderbilt University School of Medicine in Nashville, Tennessee, told Reuters Health.Mustard-family vegetables are high in vitamin C and fiber and also contain other nutrients that may have health benefits.The study, published in the American Journal of Clinical Nutrition, is based on a survey of nearly 135,000 adults from Shanghai, China.Participants filled out questionnaires about their eating habits and health history, and the researchers then divided them into five categories according to how much produce they ate.Over five years, four percent of the people died. Those who downed the most vegetables or fruits, however, were 15 percent less likely to die over that period than those who ate the fewest.For mustard-family vegetables, there was an even bigger difference in death rates between people with high and low intakes.The researchers found a similar pattern when they looked at people dying from heart disease -- about a quarter of all deaths in the study. But there was no evidence that eating fruits and vegetables was linked to cancer risk.According to Dr. Lydia Bazzano, who was not involved in the study, the results are promising. But they don't prove that just eating more fruit and vegetables will necessarily make people live longer."Unmeasured health habits may account for some of the association,"Bazzano, of Tulane University Health Sciences Center in New Orleans, told Reuters Health.The researchers did try to rule out alternative explanations -- such as age, weight, exercise, vitamin use, and smoking -- but acknowledge there could be more factors at play.Still, they encourage people to eat more produce, especially vegetables from the mustard family, as a step toward living longer, healthier lives.Heart disease is the leading killer worldwide, causing more than 600,000 deaths every year in the U.S., according to the Centers for Disease Control and Prevention. The CDC recommends eating two to four cups of fruit and vegetables daily.
SOURCE: http://bit.ly/isQvG1 American Journal of Clinical Nutrition, online May 18, 2011

Jul 5, 2011

Could a Diet Help Prevent Alzheimer's?

The low-fat, low-glycemic diet often promoted for general health and well-being may lower the risk of developing Alzheimer's disease if adopted early in life, researchers say.
But starting such an eating plan after symptoms surface doesn't seem to help prevent deterioration of brain function, according to new research published online June 13 in Archives of Neurology."
This is not the first time this concept has emerged, that things you do in midlife or earlier on may have effects later on," said Dr. Marc L. Gordon, chief of neurology at Zucker Hillside Hospital and an Alzheimer's researcher at the Feinstein Institute for Medical Research in Manhasset, N.Y." For example, we know that midlife obesity is associated epidemiologically with a higher risk of late-life dementia," he continued. "Whether that's causal or an effect of the disease is open to speculation, but it suggests that there may be periods of vulnerability that are different in different times in the life span."
Although numerous studies have probed connections between lifestyle factors and cognitive ability, no solid proof yet exists that diet (or much else) can prevent Alzheimer's, the most common form of dementia among the elderly. A low-glycemic diet, which focuses on eating fruits and vegetables, whole grains and lean meats, avoids spikes in blood sugar and is said to promote feelings of fullness.
A U.S. National Institutes of Health conference convened last spring concluded that, for now, older age is the leading known risk factor for Alzheimer's disease. A gene variation is also tied to increased risk for the brain disorder, the NIH review said. Experts at the conference stressed that the general public should still focus on avoiding behaviors already linked to other chronic diseases.This new study looked at the effect of different diets on biomarkers associated with Alzheimer's, such as blood sugar levels, cholesterol and blood lipid levels. The researchers also tested memory after participants followed the assigned diets. Twenty healthy adults and 29 with mild memory problems that could be predictive of Alzheimer's followed either a high-fat, high simple-carbohydrate diet ("HIGH" diet) or a diet lower in fat and simple carbohydrates ("LOW" diet). After four weeks, healthy participants on the LOW diet had changes in biomarkers, including insulin and lipid levels in the blood, which were moving away from those normally associated with dementia. In participants with mild cognitive impairment, this diet had the opposite effect.Commenting on the study, Dr. Suzanne de la Monte, professor of neurosurgery and pathology at Brown University and Rhode Island Hospital in Providence, said it remains to be seen if the changes noted in this study actually translate, over the longer term, into differences in risk for developing Alzheimer's disease.
The bottom line, though, is the same as it's been for eons: A healthy diet lowers your risk of type 2 diabetes, heart disease, cancer and maybe even Alzheimer's.That means staying away as much as possible from processed foods, de la Monte advised.A second study, in the same issue of the journal, also looked at biomarkers and found that different levels were associated with different measures of cognitive function associated with Alzheimer's disease.
This finding could help improve diagnosis of Alzheimer's, which now relies mostly on clinical observation.
SOURCES: Marc L. Gordon, M.D., chief, neurology, Zucker Hillside Hospital and Alzheimer's research, the Feinstein Institute for Medical Research, Manhasset, N.Y.; Suzanne de la Monte, M.D., professor of neurosurgery and pathology, Brown University and Rhode Island Hospital, Providence, R.I.; June 13, 2011, Archives of Neurology, online

Jul 1, 2011

FDA Approves HER2 Test for Breast Cancer

The genetic test allows for the measurement of the number of copies of the HER2 gene in breast tumor tissue, enabling clinicians to make more informed decisions about whether a patient would be a candidate for Herceptin therapy.

Jun 20, 2011

Scientists Identify Genes Linked to Migraines

Inheriting any one of 3 gene variants raises risk for severe headaches by up to 15%, researchers say.
Researchers have identified three genes linked to migraine headache and found that people who inherit any one of these genes have a 10 to 15 percent greater risk for the condition.
Migraine headache -- an abnormality in the response of nerve cells to stimuli -- is characterized by recurring severe headaches, which often result in nausea as well as sensitivity to light and sound.In examining genetic data from more than 23,000 women, including over 5,000 migraine sufferers, the researchers found an association between the headaches and variations in three genes: TRPM8 (which plays a role in sensitivity to cold and pain), LRP1 (a gene involved in the transmission of signals between neurons) and PRDM16.
"While migraine remains incompletely understood and its underlying causes difficult to pin down, identifying these three genetic variants helps shed light on the biological roots for this common and debilitating condition," the study's lead author, Dr. Daniel Chasman, assistant professor in the preventive medicine division at Brigham and Women's Hospital and Harvard Medical School, said in a hospital news release.
One migraine expert called the findings "very exciting." "The thinking for a long time was that migraine is most commonly a multi-genetic condition with potentially many genetic variations that contribute," noted Dr. Audrey Halpern, clinical assistant professor in the department of neurology at NYU Langone Medical Center in New York City. "We clearly understand now that migraine is a condition characterized by disordered sensory processing."Although the study authors said the findings are encouraging, they noted that more research is needed to better understand exactly how each of these three genes is associated with migraine.Halpern agreed that much more study lies ahead to unravel the genetics of migraine. "This current research will help us more fully understand what happens during migraine, but there is also much more to learn," she said. "We've always known it's a genetic condition -- but the last 10 years we've learned it's a neurological condition. This study brings those two ideas together."
The report is published in the June 12 online edition of the journal Nature Genetics.
SOURCES: Audrey Halpern, M.D., clinical assistant professor, department of neurology, NYU Langone Medical Center, New York City; Brigham and Women's Hospital.

Mar 1, 2010

Pharmacogenomics: Personalized Medicine at the Corner Drugstore

MayoClinic.com, GoogleNews.com, February 24, 2010, by Carrie A. Zabel – Personalized medicine offered at your local drugstore?

Two large prescription drug companies have announced plans to offer genetic testing as part of the prescription-filling process. The testing will center on an emerging science, pharmacogenomics, which studies drug response based upon an individual’s genetic make-up. Pharmacogenomic testing is already used for some commonly prescribed drugs such as Tamoxifen and Warfarin.

The process would use a pharmacy benefits management company that would contract with large drugstore chains. When certain prescriptions come in, the company would contact the physician to let them know a genetic test is available, which may help them to more appropriately prescribe that medication. The individual may then be offered the genetic testing, but it wouldn’t be required.

Supporters say this will improve patient safety, health outcomes and decrease overall health care costs by using the right medications in the right patients. It may also provide an opportunity to advance the field of pharmacogenomics by collecting data on genetic testing results and drug effectiveness.

Others are concerned about the privacy of genetic testing information and say the science of pharmacogenomics is premature. Drug metabolism isn’t only based on our genetic make-up, but is affected by many additional factors, such as body size and age. And, since pharmacogenomics is a relatively new science, insurance companies may not reimburse for the cost of genetic testing.


Carrie A. Zabel, M.S., C.G.C., Genetic Counselor

Feb 16, 2010

Identification of bipolar risk gene

A collaboration, led by scientists at the Garvan Institute of Medical Research and the University of New South Wales (UNSW) in Sydney, has discovered the first risk gene specifically for bipolar disorder, also known as manic-depressive illness. This means that people who have a particular form of this gene are twice as likely to develop the disease.

Lead author, Dr Ian Blair, says: “We are the first group in the world to take a multi-faceted approach to identify a bipolar risk gene - we used a number of families, unrelated patients, and therapeutic drug mouse models. Each of these three lines of investigation led us to a gene called FAT.”

Contributing author Professor Phil Mitchell, Head of Psychiatry at UNSW, says: “Over the last twenty years we have collected blood samples from 67 families right across Australia. This amounts to hundreds of family members (904), some of whom are spread across four generations. This was a strong starting point in our hunt for a Bipolar gene.”

"We know that the FAT gene codes for a protein that is involved in connecting brain cells together, what we need to do now is find out exactly how it contributes to the increased risk of bipolar disorder,” explains Dr Blair.

While other scientists have found genes associated with Bipolar, most of them haven’t stood up to scrutiny. The Sydney discovery has been verified in four independent study groups: two in the UK, one in Australia, and one in Bulgaria.

Bipolar disorder is a major psychiatric illness affecting around two people in every 100. Tragically, around one in six people suffering from the condition will commit suicide.

Mood-stabilising medications are typically prescribed to help control bipolar disorder. Lithium was the first mood-stabilising medication approved by the U.S. Food and Drug Administration (FDA) for treatment of mania. For decades it has been widely prescribed for the treatment bipolar disorder, yet no one knows for sure why it works.

“Lithium has a number of severe side effects that include tremor and weight gain. Kidney dysfunction may develop in a small proportion of patients when it is administered for long periods of time,” says Professor Mitchell.

This new research has raised the possibility that lithium exerts its therapeutic affect by altering FAT gene expression, as well as the expression of genes encoding FAT’s protein partners.

“Once we understand exactly what the FAT gene does, we will be able to develop better diagnostic tests for bipolar disorder. In the future, we hope our research will lead to new, targeted medicines specifically for bipolar disorder that don’t have the unpleasant side effects that lithium has,” says Dr Blair.

http://www.unsw.edu.au/

Feb 5, 2010

Paving the Way for Personalized Medicine

On Thursday, the Secretary’s Advisory Committee for Genetics, Health, and Society at the Department of Health and Human Services will meet to discuss a set of reports on the future of genomic medicine. The meeting will cover a range of important issues such as the impact of affordable whole-genome sequencing; comparative effectiveness research; genetics education for healthcare providers, patients, and public health workers; and the sharing of genomic data across multiple sectors including research, industry, and healthcare services.

SACGHS has formed a task force to address the clinical utility of genetic testing—that is,.the usefulness of genetic tests for helping doctors choose more effective interventions for their patients. Assessing clinical utility is an important component of both personalized medicine and comparative effectiveness research, which analyzes interventions head-to-head to see which work better for different patients. The goal is to improve comparative effectiveness research by incorporating genetic tests, which would allow physicians to tailor treatments to individual patients based on their own DNA.

The Personalized Medicine Coalition held a conference last fall to promote the alignment of comparative effectiveness research with personalized medicine. This alignment is also a crucial aspect of the recommendations issued by the Institute of Medicine, which promoted research on both “diseases and conditions with the greatest aggregate effect on the health of the U.S. population, but also less common conditions that severely affect individuals invulnerable subgroups of the population.”

The Center for American Progress has also recognized the importance of ensuring that CER can “accelerate the discovery of approaches to individualized medicine and help providers cater to the specific needs of patients.” This will move medicine beyond the “one size fits all” therapies that result from the research provided by pharmaceutical companies to the FDA. SACGHS is taking an important step forward by identifying ways to assess the clinical utility of genetic tests. This was one of several recommendations CAP has made not just for advancing personalized medicine but also for improving the quality of genetic testing in the report, “Genetic Information Non-Discrimination.”

Genetics education and training will also be a major part of the SACGHS meeting agenda. The task force outlined its action plan in July of 2008 and has since set out to identify the needs of healthcare providers, the public health workforce, and the general public for genetic education. The task force also identified various types of case studies that it will use to analyze the current information gaps in genetic testing. This will require exploring the best way to gather and disseminate information about pharmacogenomic testing, newborn screening, diagnosis of single gene disorders, direct-to-consumer testing, and population genetics. The task force plans to release their report in the coming months. This is an important step, as the public must be “informed and educated about personalized medicine through outreach efforts, opportunities for public comment or input, and most importantly through transparency.”

Data sharing is also a major component of the agenda. Representatives from government, academia, health care systems, industry, and consumer groups will present different models for sharing genomic information. This will be followed by a discussion of health information technologies that aim to efficiently connect the data among these multiple sectors. In “Paving the Way for Personalized Medicine,” my co-author and I addressed both the positive developments as well as the missed opportunities on this front. In particular, we noted that HHS’s Health IT Standards Committee has not properly collaborated with outside networks that are working to devise consistent nomenclature so that genomic data can be utilized through health IT. We recommended this kind of collaboration so that HHS can leverage the expert resources available for combining cutting-edge genomic science with health IT.

The face of medicine is changing at a breakneck pace and a forum like the SACGHS meeting allows scientists, policymakers, innovators, service providers, and patients to work together to ensure that this new era of medical innovation serves the common good by being safe, effective, efficient, and equitable.

Feb 2, 2010

A gene test that predicts the risk of a stroke

Adults at risk of either prostate cancer or an erratic heart beat that can lead to strokes can now be identified early by genetic testing. About one in 20 elderly people suffer from atrial fibrillation, a condition in which turbulent blood flow raises the risk of blood clots, which can then lodge in the brain and cause a stroke.

Now an Icelandic company, deCODE, has announced in the journal Nature that it has found a variation in the human DNA sequence which raises the risk of atrial fibrillation, and used it as the basis of a test which will make it possible to identify those who will benefit the most from treatment. The firm's researchers found two "spelling mistakes" or single-letter variations in the human genetic code which increase the risk of atrial fibrillation by about 70 per cent and 40 per cent, doubling that risk if two copies of the variants are carried.

Because of the link with stroke, the company believes testing for these variants will provide doctors with a cost-effective means of identifying those who should be intensively monitored and reduce their risk by taking anticoagulant drugs. Passing abnormalities in heart rhythm are difficult to detect in many patients and it is impractical and too costly to conduct extended cardiac monitoring, even in patients who have had a stroke. The "spelling mistakes" in DNA linked with the risk were found through analysis of more than more than 300,000 common single-letter DNA changes in more than 5,000 Icelanders and were replicated in a further worldwide study of 18,000 subjects.

Dec 7, 2009

Overweight and Obesity

Obesity definition is very straightforward. Obesity is simply defined as being overweight. It signifies that excessive amounts of fat are collected in your body, which leads to the overmuch body weight. An individual’s weight must be in balance with his or her height, which entails within the body mass index (BMI). The ideal BMI goes between 18.5 to 24.9. So, in clinical terms Body mass index of 30 and above is defined as obesity.Obesity has bad effects on the general health and lifestyle of a person. People who are obese become very inactive as they realize it hard to take part in great number of everyday activities. They cannot move easily, they are all the time exhausted and they are put in risk of becoming sick with diverse kinds of illnesses ranging from cardiovascular, cancer, diabetes, and lots of others.

What are the causes of obesity. As already stated that most common reasons for obesity can be inactive lifestyle, high intake of calories and even scientific reasons (like psychiatric, medical and genetic causes). As mentioned above, a inert and unmoving lifestyle is the first on the list of causes of obesity. An individual finds it troublesome to exercise or go in for some sport, which step by step has negative influence on his weight making him obese.Genetics or heredity is another cause of obesity. It has been found out that the gene for Obesity has been circulated from generation to generation. Thus, the children whose parents are obese show a tendency to be obese.

People who are afflicted with genetic factors for obesity have many problems with losing weight in the long term. What is more, obesity may appear because of some psychological problems. It signifies that people show a tendency of overeating themselves when they are hopeless, upset, enraged, even weary with something that, consequently, leads to obesity. As well, several diseases and conditions like Cushing’s syndrome, Hypothyroidism, Depression, and certain neurological problems cause gluttony which successively causes storing of too much fat in the body.
But, the most general reason why people overeat is that they lack time to eat healthy food as they are overcharged with many responsibilities. Wild schedules have given to the use of fast and processed food, which, on one hand, don’t have enough vitamins and minerals and, on the other, has a high amount of calories.

So, how may a person eliminate obesity? Obese people think that they will be fat till the end of their life and that they will never slim down. Of course this is nonsense, and there is a solution. You may easily cure obesity on condition that provided that you are well organized, have a strong will, and on condition that you comply with the regulations that you must follow before you decide to begin with a diet. It is most important to recognize the problem and then go to your doctor who will will best advise what to do considering your obesity issue.

Fortunately, there are great numbers of weight loss plans today, which show outstanding results. Or you may even select some other methods that fit your needs, among which some may be very extreme like obesity surgical process or ingestion of anti-obesity drugs. Very recently, genetic analysis is proving to have some very good efefcts on weight loss plans. For more information www.genebright.com

Nov 28, 2009

Genetica: test del Dna per scoprire l'infedeltà. Laboratorio invece del detective

Roma, 20 nov. (Adnkronos Salute) - Il tradimento coniugale si dimostra nel laboratorio d'analisi. Accade in Messico dove alcuni centri di diagnosi puntano alla conquista di un nuovo mercato, quello dell'infedeltà, proponendo test del Dna ad hoc per dimostrare scientificamente l'esistenza di un'amante. Il coniuge che ha un sospetto, infatti, si rivolge direttamente ai laboratori portando un indumento intimo, un lenzuolo, un bicchiere o persino un chewing-gum masticato per cercare tracce di saliva, sperma, peli o capelli dell'altro.

Con specifici test del Dna, consentiti nel Paese sudamericano anche senza l'autorizzazione dell'interessato, si può poi determinare se le tracce trovate appartengono al cliente o a qualcun altro. Queste analisi, pronte in circa una settimana, posso costare dai 200 ai 500 dollari (dai 135 euro ai 335 euro circa).

Questo nuovo business, appena avviato, in Messico ha avuto un successo immediato. "La richiesta di 'test d'infedeltà' - spiega Jorge Guillen, che dirige uno dei laboratori che propone queste analisi - è in continuo aumento. Mi è capitato di avere 50 richieste in una sola giornata. Ma è una cosa nuova per molti e ci sono molti fraintendimenti: molti clienti vengono da noi perché credono che l'infedeltà sia scritta nei geni".

Nov 20, 2009

Out of the hat of medical research

Of many interesting stories for us to blog about this week -- so many that they'll be spilling over into next week -- here's one that seems to represent a more sensible approach to disease than the relentless focus on genetics that we so commonly see. It's about a new effort by pharmaceutical companies to invest in vaccine development. The AP story says

Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.

Another story of what seems to be money well-spent appears on the BBC website. Researchers have developed a new-fangled lab-on-a-chip that will allow easier, faster and cheaper diagnosis of dozens of diseases.
The device relies on an array of antibody molecules that are designed to latch on to the protein-based molecular markers of disease in blood.
The antibodies are chemically connected to molecules that emit light of a specific colour when illuminated - but only when they have bound to the disease markers.

Some of the vaccines in the pipeline won't pan out, but some surely will, and we can imagine the lab-on-a-chip device being useful in many settings, including medically underserved areas, so we find these stories rather heartening. The money being invested is private, not taxpayer money, but not long ago a lot of pharmaceutical money was being bet on personalized genomics, and so on, which our regular readers will recognize as efforts we wouldn't have put our money on. So, it's good to see that following the money takes us in a different direction these days -- industry sees a lot more promise in preventing and treating infectious disease than in fixing genes. Indeed, a lot more disease seems to be infectious than the age of genetics led us to believe.

The Fall of deCode Genetics
It's interesting to juxtapose these two stories with this story from the Wednesday New York Times that reports on the demise of a company established to "exploit the promise of the human genome", that is, to profit from what it could learn about genetic disease from the genealogies of Iceland. Predicated on the idea that common genetic variants would be found to explain most complex disease, deCode Genetics set out to find those variants in Iceland and then develop drugs to target them. But, it turns out that complex disease is too complex for that. Again, regular readers won't be surprised if we find it hard to suppress a little "told you so".

Now, here we want to be careful about the concepts -- and it's related to central issues in The Mermaid's Tale. Life is lived, day to day, on the molecular level. Infection is essentially attack from without, and the immune system tries to recognize molecular signatures of the invading soldiers, to latch onto them and destroy them. Vaccines traditionally help the immune system do that, by exposing it to harmless mimics of the real thing (dead viruses, so to speak).

There are countless infectious diseases, affecting of most body systems, and more and more complex 'chronic' diseases that were thought to be 'environmental' or 'genetic' in the traditional senses, seem to be turning out to have infectious or inflammatory components. Thus, enhanced abilities to make vaccines could have farther-reaching implications than has been thought.

The immune system is 'genetic' of course, and its functions are fairly close to genes in many ways. But there may be other and perhaps even surprising ways this subject can bring us back to genetics. We'll deal with them in a post in the near future....

Oct 30, 2009

Learning of Risk of Alzheimer’s Seems to Do No Harm

A genetic test that can find an increased risk of Alzheimer’s diseasedoes no psychological harm to people who take it, even if they test positive for a risky gene, a new study finds.

The results challenge views long held by the medical establishment, which has discouraged people from being tested, arguing that the test is not definitive, that it may needlessly frighten people into thinking a terrible disease is hanging over them and that testing is pointless anyway because there is no way to cure or prevent the dementiacaused by Alzheimer’s.

Follow the lonk and read the full article.

Oct 28, 2009

As genetic medicine races ahead, docs are left behind

Genetic tests that can help predict and refine a patient's response to drug therapy may be the first big thing in personalized medicine. But the vast majority of physicians don't know how to use them, a new survey finds.

Oct 25, 2009

Smart Genetics Shuts Its Doors

Direct-to-consumer genetic testing company, Smart Genetics, has gone out of business.
The two-year-old company sold HIV Mirror and Alzheimer’s Mirror, DNA tests for HIV progression to AIDS and Alzheimer’s risk respectively.I first wrote about HIVmirror in June 2007. Aimed at HIV+ individuals, the test analyzes the CCR5 Delta32 and CCR2-64I genetic variants previously shown to slow the progression of HIV infection to AIDS.
Alzheimer’s Mirror examined the APOE gene.CEO and co-founder Julian Awad first received funding for the company while at the Wharton School of Business. He was later profiled by CBS News for Alzheimer’s Mirror and found that his own personal lifetime risk of Alzheimer’s disease is about 9 to 10 percent compared to 15% for the general population.
Ironically, he was also mentioned in a Wharton article from 2007 – Can Anyone Make Sense — or Money — Out of Personal DNA Testing?
Apparently not.

by Dr. Hsien-Hsien Lei

Oct 23, 2009

Jumping On Genetic Testing: The War of the SNPs

How many SNPs does it take to provide a definitive disease risk profile? Quite a few, apparently, as companies continue to pile them higher and deeper into genetic tests. Firms have bet that these tests will be widely adopted by physicians and the public to predict everything from risk of lung cancer among smokers, to prostate cancer, to Alzheimer’s disease, to baldness.

All told, about three dozen companies claim that they can provide genetic testing that predicts an individual’s risk of developing almost everything. “There is a bit of a wild wild west going on in terms of some of the DNA testing that’s out there,” said Francis S. Collins, M.D., Ph.D., the newly appointed NIH head, in an interview with CBS News in September 2008 with regard to a new offering from Smart Genetics purporting to predict susceptibility to Alzheimer’s disease (AD).

“Some of it is done by reputable companies, but there are some that are even unscrupulous who will offer you tests or DNA variations that, frankly, you’re not sure what they mean at all.” Smart Genetics stopped offering its controversial Alzheimer’s Mirror genetic test just eight months after introducing it, and the company subsequently shut its doors.

(Genetic Engineering & Biotechnology News)

Oct 13, 2009

CyGene Launches New Website for Direct-to-Consumer Genetic Test Marketing

CORAL SPRINGS, Fla., Aug. 26, 2009 (GLOBE NEWSWIRE) -- CyGene Laboratories Inc. (Pink Sheets:CYGE) today announced that it has launched a new website, www.cygenedirect.com, where consumers can get information and order predictive genetic tests geared to inform consumers about specific options to help improve health, while maintaining anonymity.  The consumer-friendly website features easy online ordering of the company's products. The site also includes comprehensive personal assessment information and details about potential benefits of the products, as well as detailed consumer information about genetics and genetic testing. The site also features links to the company's blog and its social media sites.  "People have a unique opportunity with CyGene to start learning about their personal genetics and how their genes may impact their lives. Generally, this will be their first brush with this exciting new field of science and our new website can help them find out how genetic testing works, which kits are best for them, and how they can be used to improve overall quality of life and athletic performance," said Martin Munzer, president and CEO of CyGene. "And our new site makes it easier than ever for people to get the information and products they're looking for with guaranteed anonymity."  The new creative direction of CyGeneDirect.com comes by way of Infinity Arts. "Our objective for CyGeneDirect.com was to re-invigorate the consumer website to be more compelling; easy to understand, navigate and relate to, while strategically improving visibility on the internet via search engines and online social mediums," said Michael Leahy, CEO for Infinity Arts.  About CyGene Laboratories Inc.  CyGene Laboratories Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method also allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available.  For more information about CyGene Laboratories and its products, visit the Company's website at www.CyGeneDirect.com.

Oct 10, 2009

Genetic Testing in France

By Tamar G. McLachlan


Well we visited The Geneticist Today; a Professor Labrune, at the Hospital Beclere (somewhere on the outskirts of Paris). Actually, it is in the direction of Versailles and my husband commented on how exciting it is to be in a place where we could hop over to Versailles after a doctor's visit. The fact that I was a.) freezing b.) nauseous c.) trying not to pass out from the bus ride kept me from agreeing enthusiastically.


We secured this appointment in the complex yet sincere way that the French do everything. After many emails and several intense consults with friends and family, I was convinced (not to mention a bit panicked) that it was essential that I be tested for a variety of genetic diseases (including the Jewish ones). Apparently, even though neither my husband nor I have any history of genetic diseases of any sort in our families, this testing is common in the USA and so we were advised to pursue it.


In my normal pre-pregnancy state I tend a TAD towards the anxious side. In my pregnant state with hormones running rampant I am pretty close to hysteria much of the time. I searched the internet, examined pregnancy books and grilled friends and family doctors at home about the dangers of genetic illnesses. Visions of deformed babies and childhood deaths haunted me. Meanwhile, my Parisian GYN looked at me blankly when I mentioned that I must be tested for a variety of diseases, a.s.a.p. She had no idea what I was asking.


True to French form, after my doc greeted my anxieties with a look of curiosity and confusion, she set off on a search through the hospital to find the answers to my questions. After a forty-five minute tour of the hospital, consulting with a variety of physicians, she returned to her office (where I was not-so-patiently waiting) to tell me that this hospital does not in fact perform such screening (what?! This is common practice in the USA!)


In fact, since it is a specialized concern, she would refer me to a genetics specialist who would give me an individual consult.


Frustrated that I couldn't just have the blood test done and over with then and there (I abhor blood tests), I grudgingly took the information and waited for my appointment. This was one of my many lessons in the French health system, which is related to the French culture in general. The French, as a whole, feel entitled to good care. They feel it is their right and their privilege to seek professional advice and help when and where they want it. Because of socialized medicine, there is no hesitancy to refer to specialists. Likewise, there is no hurry to pack many patients into a short time frame, scheduling appointments 15 minutes apart as in the USA.


In two months, I have visited my GYN four times and only once has it been for an actual exam. The others were all consults or opportunities for me to address concerns and get information. Two of these consults included my husband. When I call my doctor, I actually reach her directly on the phone. If I have anything other than a brief question, she schedules an appointment to talk in person. Sometimes these appointments last up to an hour. My private insurance (since I don't qualify for social security) covers 90% of all my care.


Therefore the entire mentality is different. French people often seek several consultations from several doctors to get different opinions. They are not restricted by primary care referrals and 15 minute sessions. Patients hold onto their own medical records, lab reports and x-rays.


So my husband and I were sent to see Professor Labrune, the Genetics specialist. We had an appointment schedule for 9:30 am and I was so anxious about finding the office and arriving on time that I couldn't sleep the night before. Clay calmly planned out our subway route. The next morning we left before dawn (the sun doesn't rise until 8:30 a.m. --a real downer in the early morning) and shivered our way to the metro. One metro and one extremely nauseating bus ride later, we found ourselves in front of what looked like a warehouse. Armed with only the Professor's name (and no other information), we wandered around the chain link fence, looking for the appropriate entrance. We finally found a sign directing us to Prof Labrune Porte 33. Hesitantly, we entered the "porte', which was actually a delivery entrance. Following a bakery delivery truck in through the door, we found ourselves in a garage, wondering where the heck the doctor's office was. We wandered our way through a door (having asked a confused delivery man where to go), which led to a maze of white hallways. By this time, I was anxious, nauseous and desperately had to use the bathroom, which luckily I found easily. No matter that it was an employee only entrance; this was a desperate situation (besides, I figured "hey I'm a pregnant lady! Back off!"), I could hear my husband asking for directions in the hallway. It turns out that we had come in through the kitchen entrance and were now in the back of the hospital cafeteria. Clearly not where Prof Labrune must be waiting.


We stumbled our way through an ER section, past a row of empty gurneys and up a flight of stairs leading to the information desk. The very friendly woman behind the desk directed us around the corner to pediatrics, where we sat, among an assortment of toddlers and parents, waiting to be seen. My husband beamed at the darling children; I tried to keep from throwing up or passing out.


"Look" I turned to him, "I'm not big on blood tests or hospitals and my French is headed out the window so if you could be the proactive team member here, that would be great. I mean, how the hell do I ask about being a carrier for Taysachs disease in French?"


I was concerned that I would be confronted with a grumpy Professor, who was wondering why we were wasting his time. I was worried that I would have to convince him to authorize the screenings for us (because in the USA, everything is about getting "authorization") and, that I would have to discuss genetics, not my forte… in French, also not my forte.


I couldn't have been more off base. The Professor was a charming, gentle, quiet and patient man who first took our family history. Then he patiently explained the various diseases we were concerned about (in too much detail), their origins (not really necessary) and the percentage of risk. I couldn't believe that we were having this conversation in French! And I actually understood it! Not that I "understood" it. I understood the words. And the context. I was just reveling in my linguistic breakthrough when he pulled out a piece of paper and started to diagram the cell mutation related to one of the diseases. (At this point I had to admit defeat. Not due to language barriers but due to my own science learning disability. Once someone starts talking cells and DNA, I start to lose it). Not wanting to be rude (he was enamored with his description of some particular cell growth), I steered the conversation back to our family trees and what tests would be appropriate for us.


This led to the obligatory piece of any professional consult in France: the paperwork. In order to be tested we must solemnly sign the agreement to show that we fully understood the solemn oath of his professional boundaries (confidentiality, professional courtesy, professional boundaries and a myriad of other issues which seemed to pertain mainly to his limitations as a mortal and not as an agent of God). Then there would be the second set of papers authorizing release of this information to my doctor, which could only be sanctioned with my personal authority. Otherwise, our test results would remain in the secrecy of Professor Labrune. He took this very seriously. An oath of privacy.


After we satisfactorily signed and sanctioned the paperwork, we were led next door to the lab technician to have our blood drawn. Just the thought of this process made me queasy, but my husband, who is quite an experienced blood donor, asserted that this was one of the most professional outfits he had ever seen. Not only were the technician (and her assistant) extremely friendly and caring, they treated us like dear friends, expressing extreme concern over my obvious distaste for the process. Offers of juice, attempts to make jokes, were all lost on me as I did my best to disassociate from the process. They even recommended an anesthetic patch that can be purchased in the pharmacy, to numb the area to be pricked.


I stumbled out of the technician's office (desperate to get away from any sign of B-L-O-O-D) and we returned to the information desk to settle our bill. Having been quoted a fee of $1000 to have this exact procedure (consult and tests) done in Boston, we were shocked to be asked to pay a total of 32.10 euros. I must have heard wrong. She must have meant 300 euros and in my light -headed state I was getting the numbers wrong. Nope. 23 euros for the consult with the Professor and 4 euros for our tests, plus a couple of euros miscellaneous. "You do have insurance that will reimburse you?" she asked me with a concerned look.


I am overwhelmed by the quality of service, professionalism and State of the Art care we have experienced here. I'm sure some of it is luck. But boy have we been lucky.

Aug 1, 2009

Will your genetic source code be open or closed?

The use of genetics in finding cures to diseases, now calledgenomics, may be the key to both your future health and economic growth.

Starting with the sequencing of a virus DNA by Fred Sanger in the 1970s, and extending to the sequencing of the entire human genome in 2001, scientists have been consumed with the task of decoding your genes, the genomes of disease, and manipulating genes to make new medicine.

Most of the work has been done in what computer scientists would call “closed source,” in that genomes are subject to patent rights.

But there have long been efforts to carve out a place for open source in the effort, starting with the donation of the Human Genome Project’s work in the government’s GenBank system. Versions of the H1N1 flu virus are alsobeing submitted to GenBank.

The open source advocates at O’Reilly point out that open source software has also been part of that mix, personifying that effort in David Dooling(above), assistant director for infomatics at the Genome Center in St. Louis. His work uses a lot of open source software.

But there is a larger question, one I want readers to weigh in on.

Where will the most progress come from? Does the path to cure lead through the private ownership of genetic codes, or will we make more progress is genes are part of the open source world?

Jul 29, 2009

Our genetic code should be no big secret

We should be less frightened of wider access to our DNA profile — those in the know are offering theirs up for public view

The 1997 movie Gattaca sets out one of the great dystopias of science fiction. Genetic technology has divided humanity. Social class is determined by DNA. The “valids”, with sound genetic profiles, dominate the top jobs and political power. The “in-valids”, with flawed genomes, form a genetic underclass.

The film’s vision highlights a deep concern about the coming genomic age: that as science reveals more about the human genetic code it will not only herald new approaches to medicine but also create new ways to discriminate and invade privacy. Employers might select candidates according to genetic aptitude. Health insurers could refuse cover to people with high-risk genomes. And personal information about our health and personalities might be revealed for all to see.

Such fears have built a consensus that ethical use of genetic information must be founded on strict privacy. If DNA profiles are to improve treatment and prevention of disease without compromising liberty, access must be controlled. They belong to individuals and should not be disclosed without their consent. The prevailing assumption is that we should guard such data closely.

It is far from clear, however, that this assumption is correct. True genetic privacy may be impossible to achieve — and many of the scientists whose work is driving the DNA revolution believe that the costs of trying will outweigh the benefits. Some are even backing their words with action, by publishing their own genetic data on the internet.

The fantasy that it is possible to prevent unauthorised access to a person’s DNA was exposed in March by Peter Aldhous and Michael Reilly, of New Scientist. Aldhous drank from a glass and gave it to Reilly, who used commercial services to extract his colleague’s genetic profile. It is illegal in Britain to test DNA like this without consent. But the process is so cheap and simple, and the chance of detection so slim, that this offers little practical protection. We leave so much DNA wherever we go that we cannot expect to keep it to ourselves. Legislation might be a deterrent, but it will not prevent unauthorised use.

Even if genetic data could be comprehensively protected, it doesn’t automatically follow that it should be. In making a fetish of DNA, we may be limiting its usefulness. If science is to unravel the medical implications of genetic variations between individuals, to personalise and improve healthcare, it will be necessary to compare the DNA sequences of hundreds of thousands of people. A culture of privacy will hold this back while secreting information that may be less sensitive than it seems.

Certainly, the great and the good of human genetics do not feel that they have much to lose by sharing this data. Some are challenging the privacy assumption by example. When the genetics pioneer Craig Venter became the first person to have all six billion DNA letters of his genome sequenced he published the lot. James Watson, the co-discoverer of the double helix, has done likewise, redacting only the status of a gene linked to Alzheimer’s because he did not want to know the information himself. Kari Stefánsson, of deCODE Genetics, which sells personal DNA tests, allows his customers to compare their data with his.

George Church, of Harvard University, has gone a stage further. The founder of the Personal Genome Project (PGP), and its first participant, has published not only his complete genome sequence but also his medical records and other physical details. He aims to recruit 100,000 volunteers to do the same.

The nine other recruits to the PGP’s pilot phase are all people who know their stuff: they include the psychologist Steven Pinker, John Halamka, Dean of Technology at Harvard Medical School, and Misha Angrist, a geneticist at Duke University in North Carolina. Another 13,000 have joined a waiting list to take part. By putting their information in the public domain, participants hope to exploit “crowd-sourcing”, the notion that allowing anyone to work on a problem will lead to it being solved more swiftly. The phenomenon underlies the success of Linux open-source software and Wikipedia. It could soon be driving genetic discoveries as well.

This will have individual benefits as well as social ones. When Church placed his medical records on the internet he was contacted by a doctor who suggested a useful change to his cholesterol medication. Interpretations of open data are more likely to help than harm.

The prophets of open-source genomics are unruffled because the perceived need for absolute secrecy is also based on a misunderstanding of heritability. While most people think of genetics as a deterministic science, this is rarely so. Most genes that influence health have a probabilistic effect, raising or lowering risk by small margins. Most people with the Alzheimer’s risk gene , for example, will not get Alzheimer’s. It would not only be wrong to judge somebody’s intellect, skills or good health by their ownership of particular genetic variations — it would be profoundly misleading.

All of us carry risky variants: there is no such thing as a perfect genome. That should help to prevent discrimination: if insurers were to exclude everyone with a raised genetic risk of this or that they would rapidly go bankrupt. If the market fails, companies can be banned by law from demanding genetic test results; the US has already done this, and the UK has a voluntary moratorium.

Nobody should be forced to reveal genetic data, which should be published only with the informed consent of the owner; the PGP takes the “informed” part so seriously that it requires participants to pass a genetic literacy test. But it is instructive that so many of those who best understand the mechanics of the genome see so little to fear. Given wider understanding of the probabilistic nature of genetics, their choice to go public is one that many more of us could emulate.